newsfilter
← Latest News
PR Newswire·

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

  • Eisai Co., Ltd. and Biogen Inc. announced findings on continuous lecanemab treatment presented at the 19th CTAD conference in Boston.
  • Five years of continuous lecanemab treatment extended the time patients remained in early Alzheimer's stages compared to natural history, with benefits accruing over time.
  • Lecanemab reduced the relative risk of progressing to the next disease stage by 36% versus ADNI data.
  • Patients receiving five years of treatment showed mean CDR-SB improvements of -1.00 points at three years, -1.78 points at four years, and -2.05 points at five years compared to ADNI decline.
  • Compared to ADNI data, 61.9% of lecanemab patients progressed from mild cognitive impairment to mild dementia or mild to moderate dementia by year five, versus 77.5% in ADNI.
  • Lecanemab reduced the relative risk of progression from early to moderate or severe Alzheimer's by 49% relative to ADNI data.
  • 62% of patients with low tau levels showed improvement in cognitive function and activities of daily living at five years.
  • Among low tau patients, 66% showed no decline on CDR-SB, 55% showed no decline on ADAS-Cog14, and 69% showed no decline on ADCS MCI-ADL after five years.
  • No new safety findings were observed during five years of continuous treatment.
  • Amyloid-related imaging abnormalities with edema/effusion (ARIA-E) incidence decreased from 13.5% in the first 12 months to 0.6% in the fifth year interval.
  • Lecanemab targets both protofibrils and amyloid plaques, distinguishing it from therapies targeting only plaques.
  • Eisai leads global development and regulatory submissions, while both companies co-commercialize the product.
  • Lecanemab is approved in 53 countries, with subcutaneous dosing forms approved in the U.S., China, and Japan as of late 2026.
  • Ongoing Phase 3 studies include AHEAD 3-45 for preclinical Alzheimer's and Tau NexGen for Dominantly Inherited Alzheimer's.
Company
Eisai Inc.
Keywords
Eisai Inc.